Model Selection for Estimating Treatment Effects
面向处理效应估计的模型选择AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接研究异质性处理效应估计及针对该目标的模型选择方法。
面向处理效应估计的模型选择AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Summary Researchers often believe that a treatment's effect on a response may be heterogeneous with respect to certain baseline covariates. This is an important premise of personalized medicine. Several methods for estimating heterogeneous treatment effects have been proposed. However, little attention has been given to the problem of choosing between estimators of treatment effects. Models that best estimate the regression function may not be best for estimating the effect of a treatment; therefore, there is a need for model selection methods that are targeted to treatment effect estimation. We demonstrate an application of the focused information criterion in this setting and develop a treatment effect cross-validation aimed at minimizing treatment effect estimation errors. Theoretically, treatment effect cross-validation has a model selection consistency property when the data splitting ratio is properly chosen. Practically, treatment effect cross-validation has the flexibility to compare different types of models. We illustrate the methods by using simulation studies and data from a clinical trial comparing treatments of patients with human immunodeficiency virus.